The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	S694-S696
Journal	Translational Cancer Research
Volume	5
DOIs	https://doi.org/10.21037/tcr.2016.10.82
State	Published - 2016

ASJC Scopus subject areas

@article{d5c9dd3ea0f242acb18f9f8c37f61516,

title = "The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better",

author = "Al-Shamsi, {Humaid O.} and Ibrahim, {Nuhad K.}",

year = "2016",

doi = "10.21037/tcr.2016.10.82",

language = "English (US)",

volume = "5",

pages = "S694--S696",

journal = "Translational Cancer Research",

issn = "2218-676X",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better

AU - Al-Shamsi, Humaid O.

AU - Ibrahim, Nuhad K.

PY - 2016

Y1 - 2016

UR - http://www.scopus.com/inward/record.url?scp=84996956143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996956143&partnerID=8YFLogxK

U2 - 10.21037/tcr.2016.10.82

DO - 10.21037/tcr.2016.10.82

M3 - Editorial

AN - SCOPUS:84996956143

SN - 2218-676X

VL - 5

SP - S694-S696

JO - Translational Cancer Research

JF - Translational Cancer Research

ER -